NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Delphia Therapeutics

Delphia Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.delphiatx.com/

Last Round

Series A

May 2, 2024

Total Funding Raised

$67M

Company Overview

Delphia Therapeutics is a biotechnology company that develops innovative cancer therapeutics using an activation lethality platform to target cancer-linked cell signaling pathways.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oncology therapeuticsdrug discoverybiotechsmall molecule therapeuticscancer researchprecision medicinedrug development pipelinebiopharmaceuticalclinical-stage biotechtherapeutic candidatesfunctional genomicstranslational studiestumor geneticspharma pipelinedrug assets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Delphia Therapeutics Comparables

Compare Delphia Therapeutics with similar companies based on industry and business-model similarity.

Delphia Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nested Therapeutics
85%
Alterome Therapeutics
81%
Tango Therapeutics
80%

Delphia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 2, 2024

Key People

Founding team and executive leadership

Kevin Marks

President & CEO

Executive Team

Delphia Therapeutics Investors

Notable investors and investment history

Delphia Therapeutics investors
InvestorRounds
GVSeries A, Seed
Alexandria Venture InvestmentsSeries A
Nextech InvestSeries A
Polaris PartnersSeries A
Alexandria Venture InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 9, 2025

    Steve Kelsey, M.D. appointed to the board of directors.

  • May 28, 2025

    Reza Mazhari appointed as the new chief business officer.

Delphia Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Delphia Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Delphia Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range28
Year Founded2022
Last FundingMay 2, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.